Avecho Biotechnology (ASX:AVE) received the initial $3 million licensing fee from generic pharmaceuticals company Sandoz for the commercial rights to the former's proprietary cannabidiol (CBD) product in Australia, according to a Friday filing with the Australian bourse.
Avecho Biotechnology is entitled to receive $16 million upon meeting certain milestones and tiered royalties ranging from 14% to 19% on net sales, per the filing.
Under the terms of the agreement, Sandoz has exclusive commercial rights for Avecho's CBD capsule product for insomnia in Australia for 10 years.
Avecho Biotechnology's shares jumped 20% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.